BIOVAXYS TECHNOLOGY CORP.BIOVAXYS TECHNOLOGY CORP.BIOVAXYS TECHNOLOGY CORP.

BIOVAXYS TECHNOLOGY CORP.

No trades
See on Supercharts
Market capitalization
‪10.16 M‬CAD
−0.110CAD
‪−11.73 M‬CAD
‪114.84 M‬
Beta (1Y)
1.02

About BIOVAXYS TECHNOLOGY CORP.

CEO
James Christopher Passin
Headquarters
Etobicoke
Founded
2018
ISIN
CA09076M1014
FIGI
BBG00L1F9PS3
BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of BIOV is 0.080 CAD — it has decreased by 5.88% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NEO exchange BIOVAXYS TECHNOLOGY CORP. stocks are traded under the ticker BIOV.
BIOV stock is 6.25% volatile and has beta coefficient of 1.02. Check out the list of the most volatile stocks — is BIOVAXYS TECHNOLOGY CORP. there?
Yes, you can track BIOVAXYS TECHNOLOGY CORP. financials in yearly and quarterly reports right on TradingView.
BIOV stock has fallen by 5.88% compared to the previous week, the last month showed zero change in price, over the last year BIOVAXYS TECHNOLOGY CORP. has showed a 60.00% increase.
BIOV net income for the last quarter is ‪−1.58 M‬ CAD, while the quarter before that showed ‪−1.49 M‬ CAD of net income which accounts for −5.79% change. Track more BIOVAXYS TECHNOLOGY CORP. financial stats to get the full picture.
Today BIOVAXYS TECHNOLOGY CORP. has the market capitalization of ‪10.16 M‬, it has decreased by 11.76% over the last week.
No, BIOV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BIOV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOVAXYS TECHNOLOGY CORP. stock right from TradingView charts — choose your broker and connect to your account.
BIOV reached its all-time high on Feb 16, 2021 with the price of 0.770 CAD, and its all-time low was 0.010 CAD and was reached on Dec 11, 2023.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOVAXYS TECHNOLOGY CORP. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOVAXYS TECHNOLOGY CORP. stock shows the neutral signal. See more of BIOVAXYS TECHNOLOGY CORP. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.